AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01893736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-hospital professional support
Description: In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
Study NCT01868555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Study NCT01893736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum telephone follow-up support
Description: Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
Study NCT01862549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for children
Study NCT01862549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study NCT05210426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: The Pilates Group completed a 10-week Pilates program. The intervention was performed in 20 sessions. In the first session, introduction and explanations regarding the principles and benefits of Pilates was made in a language that preschool children can understand. Exercises were supervised, and they were taught via gamification. In addition, the participation of the children was encouraged and stickers were given to increase their motivation at the end of the sessions. No adverse events occurred during intervention. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week.
Study NCT02664870 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopy
Description: Arthroscopic Surgery on the hip, shoulder, or knee
Study NCT02664870 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroplasty
Description: Total hip, shoulder, or knee arthroplasty
Study NCT04383938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) + Pembrolizumab
Description: APR-246 D1-4 + Pembrolizumab D3
Study NCT03946085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lumega-Z
Description: A specially-formulated carotenoid supplement formula that utilizes a micronized, lipid-based liquid form of delivery.
Study NCT03946085 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AREDS2
Description: A commercially-available multivitamin soft gel formula.
Study NCT01702506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib fasted
Description: Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
Study NCT01702506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib fed
Description: Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
Study NCT01702506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib+antacid
Description: Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
Study NCT03649009 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days after recruitment and randomization.
Study NCT03649009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization
Study NCT03649009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
Study NCT03649009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
Study NCT01823991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VitaBlue™
Description: Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
Study NCT03649009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: If patient develop nausea after IV thiamine infusion, IV metoclopramide 10mg stat will be given. If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given.
Study NCT01554995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371
Description: LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
Study NCT01554995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid 600 mg (Cohort 9) none
Study NCT03424122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
Study NCT01823991 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people.
Study NCT02169609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab. Immunotherapy
Description: Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy.
Study NCT02354417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: ProHema-CB
Description: Each subject will receive one administration of ProHema-CB unit transplant.
Study NCT01823991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza®
Description: Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
Study NCT01169402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 25mg/kg intravenously once weekly while on ECMO
Study NCT03424122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
Study NCT01653509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acyclovir patch
Description: Patch containing acyclovir
Study NCT01653509 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Patch without acyclovir
Study NCT04721600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evoke Radiofrequency Device
Description: Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin
Study NCT01928732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Description: CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.
Study NCT01928732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure (PE)
Description: PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: The world is an utterly dangerous place, and I am completely incompetent and unable to cope with stress. In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure.
Study NCT03252210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Stereoscopic Localization
Description: 1.Confirm the nodule's location and measure the distance between the nodule and anatomic landmarks from the CT scan. 2.According to the results of the first step，confirm the needle puncture site of the chest wall. 3.After general anesthesia and Patient positioning are completed, the needle is then inserted via the needle puncture site .
Study NCT01008917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib with temsirolimus
Description: Weekly intravenous temsirolimus with daily oral sorafenib
Study NCT01682928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV/Oral Hydration and Bedrest
Description: * Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs
Study NCT01682928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Description: * Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs~* HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy
Study NCT01209156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] PBR111
Description: Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of \[18F\]PBR111, followed by PET imaging.
Study NCT02151084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Study NCT02151084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02151084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01197924 — intervention group
Intervention type: OTHER
Intervention: IRMf Bold
Description: IRMf BOLD of the working memory
Study NCT04475406 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: PICF (Periopaper)
Description: After the plaques and soft attachments around the implants were removed, the implants were isolated using cotton rolls and dried with an air spray. The PICF was collected from the mesio-buccal region of the implant using periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.
Study NCT04475406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PICF (Periopaper)
Description: After the plaques and soft attachments around the implants were removed, the implants were isolated using cotton rolls and dried with an air spray. The PICF was collected from the mesio-buccal region of the implant using periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.
Study NCT04475406 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Subgingival plaque, Gracey curette (Hu-Friedy)
Description: After collecting the PICF, the supragingival plaque was carefully removed using a sterile scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal region of the implant using a sterile plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C until the analysis day.
Study NCT04475406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival plaque, Gracey curette (Hu-Friedy)
Description: After collecting the PICF, the supragingival plaque was carefully removed using a sterile scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal region of the implant using a sterile plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C until the analysis day.
Study NCT04475406 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clinical data, williams probe PCPNU (Hu-Friedy)
Description: A single calibrated examiner performed all (full-mouth and site-specific) clinical measurements (B.K.), including probing depth (PD), clinical attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL).~The values of PD and BOP were measured from four sites of each implant (mesial, distal, buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal probe. The PD was recorded as the distance from the base of the peri-implant to the side of the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of all patients were taken, and differences in the marginal bone level between radiography images after implant placement and 3 years later were evaluated. Original films and images taken later were taken with the same angle for standardizaton.
Study NCT04475406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical data, williams probe PCPNU (Hu-Friedy)
Description: A single calibrated examiner performed all (full-mouth and site-specific) clinical measurements (B.K.), including probing depth (PD), clinical attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL).~The values of PD and BOP were measured from four sites of each implant (mesial, distal, buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal probe. The PD was recorded as the distance from the base of the peri-implant to the side of the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of all patients were taken, and differences in the marginal bone level between radiography images after implant placement and 3 years later were evaluated. Original films and images taken later were taken with the same angle for standardizaton.
Study NCT03424122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
Study NCT03424122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib administered orally once daily.
Study NCT04268745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Progressive balance training within virtual environments
Study NCT04268745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Vestibular Rehabilitation
Description: Progressive balance training and gaze stability exercises
Study NCT04855383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles
Description: Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
Study NCT00988364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20mg daily for 3 months.
Study NCT00988364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vytorin
Description: Vytorin 20/10mg daily for 3 months.
Study NCT00988364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet daily times 3 months.
Study NCT00988364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10mg daily for 3 months.
Study NCT03137693 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Breast-conserving Surgery
Description: Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
Study NCT03263767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m² Intravenous 5 days from Day-6 to Day-2
Study NCT03263767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 30 mg/m² Intravenous 5 days from Day-6 to Day-2
Study NCT03263767 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Full body irradiation
Description: 2 grays at Day-1
Study NCT03263767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14 mg/kg intravenous 2 days at Day - 6 and day -5
Study NCT02192918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Airbrush
Description: The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
Study NCT02192918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Airbrush Plus
Description: The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
Study NCT02192918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Airbrush
Description: The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
Study NCT03344042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100mcg Fentanyl
Study NCT03263767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg intravenous 2 days at day +3 and day +4
Study NCT00218972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic interval training